A serial entrepreneur, Dimun has over 30 years of outstanding operational, business development, and financial experience in the healthcare industry. Over the last 20 years, Dimun has been an investor and mentor to several emerging growth medical enterprises that have since matured to commercial status and became publicly traded companies, acting either as the founder or participating in the finding of 21 medical device firms. Of these enterprises, eleven were acquired and four have remarkably become public companies.
In addition, since 2001 he has served as the Chairman of Nascent Enterprises, a group of medical industry focused entrepreneurs committed to the successful commercialization of particularly promising medical device inventions. Prior to that he served as Executive Vice President & Chief Financial Officer of Vital Signs, a publicly held anesthesia, respiratory and sleep apnea medical device firm. GE Medical acquired Vital Signs in 2008 for approximately $900 million. In 1991, Dimun held positions as a Certified Public Accountant with national accounting firms and served as Senior Vice President for an international merchant banking firm specializing in acquisitions and mergers.
“We are thrilled to welcome Tony to our Board of Directors, and look forward to his contribution to MELA Sciences. As a seasoned executive in the healthcare industry, Tony has significant leadership experience managing growing businesses, achieving sustainable revenue growth and driving operational improvements. I believe he will bring meaningful value to MELA Sciences and to our Board of Directors,” stated Robert Coradini, Interim Chief Executive Officer of MELA Sciences.
“I am pleased to be joining MELA Sciences’ Board of Directors, and look forward to contributing to the company’s success and commercial efforts,” commented Dimun. “MELA Sciences is at an exciting stage in its development as a company, and is emerging as a true leader in the field of diagnostic devices for melanoma detection.”
Dimun has been a director of several public companies, including Bionx Implants, Vital Signs, Colorado MedTech, ISS Surgical Systems, Photomedix, as well as a number of privately held companies in the healthcare arena. Additionally, he has served on the Board of Advisors of the Rutgers University Technology Center & the Biomaterial Institute of Rutgers University and, through Nascent Enterprises, provided the University of Pennsylvania and other institutions with guidance and entrepreneurial assistance in order to commercialize their medical technology.
For more information, please visit www.melasciences.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
